Profund Advisors LLC Has $872,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Profund Advisors LLC trimmed its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 19.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,947 shares of the company’s stock after selling 9,353 shares during the quarter. Profund Advisors LLC’s holdings in Intellia Therapeutics were worth $872,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Avidity Partners Management LP boosted its holdings in Intellia Therapeutics by 18.0% during the fourth quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after acquiring an additional 68,334 shares during the period. Opaleye Management Inc. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $3,019,000. Vanguard Group Inc. increased its position in Intellia Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock worth $254,514,000 after buying an additional 155,579 shares during the period. Comerica Bank lifted its holdings in shares of Intellia Therapeutics by 853.6% during the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after buying an additional 33,214 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $206,000. 88.77% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 24th. Stifel Nicolaus cut their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Royal Bank of Canada reissued an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Finally, Truist Financial reissued a “buy” rating and set a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $61.77.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $21.47 on Wednesday. The company’s fifty day moving average is $23.06 and its 200-day moving average is $23.96. Intellia Therapeutics, Inc. has a 52 week low of $19.21 and a 52 week high of $34.87. The company has a market capitalization of $2.07 billion, a PE ratio of -4.01 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The company’s revenue was down 48.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.40) earnings per share. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.19 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.